Skip to content
    Back to Database
    Pump and Performance IngredientsFermented

    VasoDrive-AP

    Also known as: IPP and VPP tripeptides, Lacto-tripeptides, VasoDrive-AP

    Casein-derived IPP/VPP tripeptides inhibit angiotensin-converting enzyme (ACE), lowering angiotensin II and supporting vasodilation.

    Last reviewed: 2026-06-23 · 1 indexed study

    Evidence Score
    62/100
    Blood pressure supportVascular functionPump
    Data Completeness3/4 · 75%
    Evidence ScoreDosageSafetyLinked Studies

    Set your location for accurate regulatory status

    Saved on this device — no sign-in needed.

    Sign in to add to stack

    Overview

    VasoDrive-AP supplies isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) lacto-tripeptides that act as natural ACE inhibitors, supporting blood pressure and vascular flexibility.

    Mechanism & Function

    Mechanism of Action

    Reduces ACE activity, lowers blood pressure (modest), and improves arterial elasticity.

    Physiological Role

    Used in pre-workouts and cardiovascular stacks for vascular support; meta-analyses confirm small but consistent BP reductions.

    Primary Pathways

    ACE inhibitionAngiotensin II reductionEndothelial functionArterial elasticity

    Performance / Health Relevance

    Multiple RCTs and meta-analyses showing 4–7 mmHg systolic BP reduction in hypertensive populations.

    Evidence Review

    Overall62/100
    Human Clinical70/100
    Meta-Analysis68/100
    Mechanistic80/100
    Real-World58/100
    Safety88/100

    Practical Use & Dosage

    Minimum Effective Dose
    5 mg combined IPP+VPP
    Optimal Range
    10–15 mg combined IPP+VPP/day
    Upper / Caution Level
    ~25 mg/day
    Timing
    With meals or pre-exercise
    Best Format
    Capsule, powder
    Bioavailability
    Tripeptides absorbed intact via PEPT1; activity demonstrated in plasma.
    Absorption Considerations
    PEPT1 intestinal peptide transport; resistant to gastric proteolysis.

    Safety & Interactions

    Side Effects

    • •Generally well tolerated

    Contraindications

    • Hypotension
    • ACE-inhibitor use (additive)

    Drug Interactions

    • •ACE inhibitors
    • •ARBs
    • •Antihypertensives

    Who Should Avoid

    • •Pregnancy

    Monitoring

    BP if on antihypertensives.

    Frequently Asked Questions

    Auto-generated from indexed evidence — dosage, safety, interactions, and more.

    When is VasoDrive-AP typically used or indicated?

    VasoDrive-AP is most commonly used for: Blood pressure support, Vascular function, Pump. Used in pre-workouts and cardiovascular stacks for vascular support; meta-analyses confirm small but consistent BP reductions.

    How does VasoDrive-AP work?

    Reduces ACE activity, lowers blood pressure (modest), and improves arterial elasticity.

    What is the recommended dose of VasoDrive-AP?

    The optimal range is 10–15 mg combined IPP+VPP/day. with a minimum effective dose of 5 mg combined IPP+VPP. Best taken: With meals or pre-exercise. Upper / caution level: ~25 mg/day.

    What are the side effects of VasoDrive-AP?

    Reported side effects include: Generally well tolerated. Monitoring: BP if on antihypertensives.

    Does VasoDrive-AP interact with medications?

    Known or theoretical interactions: ACE inhibitors; ARBs; and Antihypertensives. Always check with a clinician before combining with prescription medication.

    Who should avoid VasoDrive-AP?

    VasoDrive-AP is generally not recommended for: Pregnancy; Hypotension; and ACE-inhibitor use (additive).

    How strong is the evidence for VasoDrive-AP?

    Evidence level: Moderate (overall score 62/100), based on 1 indexed study on SuppIndex.

    Research & References (1)

    Lactotripeptides IPP and VPP on blood pressure: meta-analysis

    Meta-Analysis2013Moderate
    PubMed

    Significant SBP reduction (~4 mmHg) and DBP (~2 mmHg) in hypertensives.

    Trademark Ingredients

    VasoDrive-AP®

    Manufacturer:

    Related Ingredients

    Other top-rated ingredients in Pump and Performance Ingredients.

    Nitrosigine®

    82/100

    Inositol-stabilized arginine silicate complex that provides sustained elevation of plasma arginine (up to 6 hours) and silicon, enhancing eNOS-mediated nitric oxide production, vascular compliance, and cognitive flexibility during physical exertion.

    Beetroot Extract

    80/100

    Concentrated source of dietary inorganic nitrate that undergoes serial reduction via oral microbiome (NO₃⁻ → NO₂⁻) and tissue-level reduction (NO₂⁻ → NO) through the oxygen-independent nitrate-nitrite-NO pathway, enhancing blood flow and exercise efficiency.

    Citrulline Malate

    78/100

    Salt of L-citrulline and DL-malic acid (commonly 2:1); citrulline raises plasma arginine and NO; malate enters the Krebs cycle and may buffer fatigue.

    Research Overview

    Moderate Evidence
    1Total Studies
    0Human Trials
    1Meta-Analyses
    2013Latest Study
    0Animal / In Vitro
    0Athlete Studies
    Primary data sourceMixed
    Pooled evidence (meta-analysis / systematic review)Yes

    Cite this ingredient

    One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.

    Stable URL

    https://thesuppindex.com/ingredients/vasodrive-ap

    SuppIndex. (2026). VasoDrive-AP: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/vasodrive-ap

    Based on 1 indexed studies · Evidence level: Moderate.

    Goal Ratings

    General Health
    Endurance
    Recovery

    Stack Compatibility

    Synergistic with L-citrulline, pycnogenol, beetroot for vascular stack.

    L-CitrullinePycnogenolBeetroot